Skip to content
Review Open access

Application of large language models in early screening of Alzheimer’s disease: a scoping review

Oct 2026 · Frontiers in Aging Neuroscience · Vol 18 · 0 citations · 47 references
Medicine

TL;DR

Large language models provide a novel technological approach for early AD screening and demonstrate potential for supporting cognitive assessment and risk identification and strengthen real-world studies, multicenter validation, and the development of model safety and ethical governance frameworks to facilitate the standardized application of LLMs in early AD screening.

Abstract

Objective To systematically map the current applications of large language models (LLMs) in the early screening of Alzheimer’s disease (AD) and to provide evidence to inform future research and nursing practice. Methods This scoping review was conducted in accordance with the Joanna Briggs Institute (JBI) methodological framework. A comprehensive search was performed in PubMed, Web of Science, Embase, Cochrane Library, ProQuest, and Scopus from database inception to April 20, 2026. Eligible studies were screened, selected, and synthesized according to predefined inclusion criteria. Results A total of 25 studies were included. The LLMs applied in these studies mainly consisted of general-purpose generative models, multimodal models, and medical-specific models. Data sources primarily included public databases, along with real-world clinical data and simulated data. LLMs were mainly applied for cognitive impairment identification, data augmentation, automated cognitive assessment, and clinical decision support, with cognitive impairment identification being the predominant application direction. Several studies employed prompting strategies including zero-shot prompting, few-shot prompting, chain-of-thought prompting, and agent-based prompting. Multimodal integration and agent-based collaborative reasoning have emerged as important research directions in recent years. Conclusion Large language models provide a novel technological approach for early AD screening and demonstrate potential for supporting cognitive assessment and risk identification. Future research should strengthen real-world studies, multicenter validation, and the development of model safety and ethical governance frameworks to facilitate the standardized application of LLMs in early AD screening.

Read PDF

Similar papers

Review Open access Oct 2026

Joint modeling approaches for predicting conversion from mild cognitive impairment to Alzheimer’s disease: A systematic review (1999-2025)

Background Mild cognitive impairment (MCI) is a critical transition stage toward Alzheimer’s disease (AD). While standard longitudinal and survival methods evaluate disease progression separately, joint modeling handles their complex interdependencies. However, no systematic review has exclusively evaluated joint model...

A. Mouiha, M. Masrour, M. Zarrouk et al. · 0 citations
Review Open access Sep 2026

Non-pharmacological interventions for cognitive function improvement in patients with Alzheimer's disease: a best evidence summary

Objective This study aimed to systematically retrieve, analyze, and synthesize evidence on non-pharmacological interventions to improve overall cognitive function in patients with Alzheimer's disease (AD), providing evidence-based references for selecting and optimizing these interventions. Methods This review followed...

Na-Na Wang, L. Dang, W. Chang et al. · 0 citations
Review Open access Sep 2026

Artificial intelligence and digital biomarkers in the early detection of Alzheimer's Disease: a systematic review

Alzheimer’s disease (AD) is the leading cause of dementia worldwide, and early diagnosis remains an important clinical challenge, mainly due to the sensitivity, cost, and availability limitations of conventional diagnostic methods. In this context, artificial intelligence (AI)-based digital biomarkers have been investi...

Matheus Sena Boaventura Fagundes, Anna Paula Torres Pedreira, M. R. L. Lopes et al. · 0 citations
Review Open access Oct 2026

Language Impairment in Alzheimer’s Disease: An Updated Narrative Review of Digital Assessment, Social Interventions, and Medical Treatment, 2016-2026

A narrative review synthesizes empirical evidence from 2016 through 2026 of language impairment in Alzheimer’s disease, highlighting the necessity of biological amyloid and tau biomarker confirmation and prioritizing standardized speech endpoints to assess disease-modifying therapies.

Blanka Klimova · 0 citations
Review Open access Oct 2026

Discourse-based assessment in clinical context for persons with Alzheimer's disease: A scoping review.

BackgroundDiscourse assessment captures communicative abilities integrating linguistic, cognitive, and pragmatic processes and is widely used to characterize communication changes in Alzheimer's disease (AD).ObjectiveTo identify and map clinically applicable methods and linguistic measures for assessing discourse chang...

Guillaume Duboisdindien, Nancy Durieux, Mireille Kieu et al. · 1 citation
Review Open access Oct 2026

AI-Powered Structuring of Clinical Information in Parkinson's Disease: An Approach Based on Large Language Models.

Advanced Parkinson's Disease (APD) is clinically heterogeneous, and many APD-defining features are recorded predominantly in unstructured neurology narratives, limiting scalable phenotyping and longitudinal analyses. An approach based on large language models (LLMs) was designed to transform free text from electronic h...

Unai Zalabarria, Angela Sáenz, Alvaro Ochoa et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.